PitchSend

Investor Presentaiton

Investor presentation First three months of 2017 Slide 67 Fast-acting insulin aspart approved in the EU and Canada, regulatory decision by FDA expected Q4 2017 • Regulatory decisions and next steps FiaspⓇ (fast-acting insulin aspart) launched in Germany, UK and Canada . Next step: Launch roll-out in more European countries • Class II resubmission of the NDA for fast-acting insulin aspart in the US on 29 March 2017 FiaspⓇ vs NovoRapidⓇ EU label characteristics Efficacy Pharma- cokinetics Safety • Next step: Regulatory decision by the FDA expected Q4 2017 Specific populations • FiaspⓇ HbA1c reduction of -0.32% compared NovoRapidⓇ of -0.15% in type 1 diabetes patients Fiasp® 1-h PPG reduction of -0.29 mmol/l •FiaspⓇ twice as fast as NovoRapidⓇ •Twice as much insulin available during first 30 minutes with FiaspⓇ • Overall safety of FiaspⓇ consistent with NovoRapidⓇ • Hypoglycaemia may occur earlier compared to other mealtime insulins •FiaspⓇ approved for pregnancy and pumps as NovoRapidⓇ Paediatric use not yet approved for FiaspⓇ and more limited geriatric use vs NovoRapidⓇ NDA: New drug application changing diabetes® PPG: Postprandial glucose; SC: Subcutaneous novo nordisk

View entire presentation